Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 10, 2025 | June 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date June 10, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-06-09 | Direct | 62,728 |
Reported balance
After 2025-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 62,728 · Balance 62,728 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-06-09 | Direct | 1,689 |
Reported balance
After 2025-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-10 · Grant · Acquired 1,689 · Balance 1,689 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-06-09 | Direct | 7,238 |
Reported balance
After 2025-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-10 · Grant · Acquired 7,238 · Balance 7,238 F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 12, 2025 16:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 7,238 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085445 · ownership.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,238 Underlying: Common Stock · 7,238 shares Expires 2035-06-09 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 16:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,689 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085445 · ownership.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,689 Underlying: Common Stock · 1,689 shares Expires 2035-06-09 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 16:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 62,728 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085445 · ownership.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,728 Underlying: Common Stock · 62,728 shares Expires 2035-06-09 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 16:13 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 5,209 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069890 · ownership.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,209 Underlying: Common Stock · 5,209 shares Expires 2034-06-03 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 16:13 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,215 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069890 · ownership.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,215 Underlying: Common Stock · 1,215 shares Expires 2034-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 16:13 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 40,282 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069890 · ownership.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,282 Underlying: Common Stock · 40,282 shares Expires 2034-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,744 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031789 · ownership.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,744 Underlying: Common Stock · 2,744 shares Expires 2033-06-29 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 640 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031789 · ownership.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640 Underlying: Common Stock · 640 shares Expires 2033-06-29 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 21,222 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031789 · ownership.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,222 Underlying: Common Stock · 21,222 shares Expires 2033-06-29 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 06:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 4,323 | $3.48 | $15,024.59 |
DisclosureSEC source: 0000899243-22-024133 · doc4.xml · nonDerivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,967 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.475 to $3.4756, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 17:07 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 6,958 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021638 · doc4.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,958 Underlying: Common Stock · 6,958 shares Expires 2032-06-06 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 17:07 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,624 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021638 · doc4.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624 Underlying: Common Stock · 1,624 shares Expires 2032-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 17:07 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 53,812 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021638 · doc4.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,812 Underlying: Common Stock · 53,812 shares Expires 2032-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:45 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,750 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023010 · doc4.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires 2031-06-07 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:45 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 408 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023010 · doc4.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408 Underlying: Common Stock · 408 shares Expires 2031-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:45 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 13,534 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023010 · doc4.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,534 Underlying: Common Stock · 13,534 shares Expires 2031-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:47 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 4,623 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016181 · doc4.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,623 Underlying: Common Stock · 4,623 shares Expires 2030-06-08 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:47 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,079 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016181 · doc4.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,079 Underlying: Common Stock · 1,079 shares Expires 2030-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:47 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 26,503 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016181 · doc4.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,503 Underlying: Common Stock · 26,503 shares Expires 2030-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 16:15 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 1,700 | $5.86 | $9,964.21 |
DisclosureSEC source: 0000899243-19-023628 · doc4.xml · nonDerivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,644 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 17:35 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,305 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0000899243-19-015820 · doc4.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,305 Underlying: Common Stock · 3,305 shares Expires 2029-06-03 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 17:35 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 771 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0000899243-19-015820 · doc4.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 771 shares Expires 2029-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 17:35 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,951 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0000899243-19-015820 · doc4.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,951 Underlying: Common Stock · 18,951 shares Expires 2029-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 16:35 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,708 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000899243-18-015766 · doc4.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,708 Underlying: Common Stock · 2,708 shares Expires 2028-06-06 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 16:35 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 632 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000899243-18-015766 · doc4.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632 Underlying: Common Stock · 632 shares Expires 2028-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 16:35 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,526 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000899243-18-015766 · doc4.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,526 Underlying: Common Stock · 15,526 shares Expires 2028-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 17:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,037 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-17-016104 · doc4.xml · derivative · entry 3 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037 Underlying: Common Stock · 1,037 shares Expires 2027-06-07 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 17:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 4,444 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-17-016104 · doc4.xml · derivative · entry 2 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,444 Underlying: Common Stock · 4,444 shares Expires 2027-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 17:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 17,776 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-17-016104 · doc4.xml · derivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,776 Underlying: Common Stock · 17,776 shares Expires 2027-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 16:30 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 4,444 | $4.50 | $19,998.00 |
DisclosureSEC source: 0000899243-17-004752 · doc4.xml · nonDerivative · entry 1 JOYCE MARTIN JOSEPH · CIK 0001300858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,944 F1 · price: Represents shares of common stock purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 17, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.